Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
NCT05758246 · View on ClinicalTrials.gov ↗
Study Summary
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway. A multicenter, randomized, adaptive allocation clinical trial to identify the most efficacious dose of the senolytic fisetin to reduce the composite cardiovascular, respiratory, and renal sequential organ failure assessment score at 1 week, and predict the probability of success of a definitive phase III clinical trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fisetin-dose 1
- DRUG Fisetin-dose 2
Study Locations (10)
Minnesota
- Ridges — Burnsville
- Southdale — Edina
- M Health Fairview St. John's — Maplewood
- St. John's — Maplewood
- University of Minnesota — Minneapolis
- HCMC — Minneapolis
- UMMC — Minneapolis
Florida
- University of Florida — Gainesville
Iowa
- University of Iowa — Iowa City
Mississippi
- University of Mississippi Medical Center — Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2026-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05758246
The ClinicalTrials.gov registry entry for NCT05758246 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 919 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05758246 reports 10 study locations spanning 4 distinct geographic areas — top geographies include Minnesota, Florida, Iowa. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05758246 about?
NCT05758246 is a clinical study titled "Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial". The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate b...
What is the current status of trial NCT05758246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2023-08-23. Estimated completion is 2026-08-23.
What conditions does trial NCT05758246 study?
This clinical trial studies the following conditions: Sepsis, Acute Infection, Organ Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05758246?
The interventions under investigation include: Placebo (DRUG), Fisetin-dose 1 (DRUG), Fisetin-dose 2 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05758246?
This trial is sponsored by University of Minnesota, which has 919 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05758246 being conducted?
This trial has 10 study locations across Florida, Iowa, Minnesota, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.